Our recently published study explains the mechanism of action of GnRH antagonist in the treatment of severe OHSS
The scientific team of Eugonia has described the only available treatment worldwide for the treatment of severe OHSS using GnRH antagonist administration.
In our new study, we provide an explanation on the mode of action of the antagonist, based on the pathophysiology of OHSS.
Our data show that GnRH antagonist causes a rapid decline of VEGF, the primary angiogenic factor responsible for the development of OHSS.
It must be noted that OHSS is the most serious complication of IVF programs. Until recently, there was no established cure for severe OHSS, which often requires patient hospitalization.
Our study was published in the official journal of the Royal College of Obstetrics and Gynaecology, UK (BJOG: An international Journal of Obstetrics and Gynaecology).
Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome,